Rights issue in Isofol Medical AB (SE) — SEK 150 million

Carnegie acted as joint bookrunner in the fully guaranteed SEK 150 million rights issue and potential over-allotment option of up to approximately SEK 30m in Isofol. Isofol Medical is a clinical stage biotech company developing arfolitixorin to improve the efficacy of standard of care chemotherapy for advanced colorectal cancer by increasing tumor response and progression free survival. June 2020.